{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:47:14Z","timestamp":1791082034952,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00520-025-09571-x","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T05:17:19Z","timestamp":1748841439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy"],"prefix":"10.1007","volume":"33","author":[{"given":"Ishani P.","family":"Kale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika M.","family":"McCauley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"3","key":"9571_CR1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1080\/09546634.2021.1898529","volume":"33","author":"TK Le","year":"2021","unstructured":"Le TK, Kaul S, Cappelli LC, Naidoo J, Semenov YR, Kwatra SG (2021) Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. J Dermatol Treat 33(3):1691\u20131695. https:\/\/doi.org\/10.1080\/09546634.2021.1898529","journal-title":"J Dermatol Treat"},{"issue":"11","key":"9571_CR2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151(11):1206\u20131212. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1916","journal-title":"JAMA Dermatol"},{"issue":"10","key":"9571_CR3","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day R, Wei-Wu Chen E, Siu M (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28(10):2377\u20132385. https:\/\/doi.org\/10.1093\/annonc\/mdx286","journal-title":"Ann Oncol"},{"issue":"4","key":"9571_CR4","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","volume":"85","author":"HT Quach","year":"2021","unstructured":"Quach HT, Johnson DB, LeBoeuf NR, Zwerner JP, Dewan AK (2021) Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol 85(4):956\u2013966. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.054","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"9571_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","volume":"25","author":"A Muntyanu","year":"2020","unstructured":"Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV (2020) Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg 25(1):59\u201376. https:\/\/doi.org\/10.1177\/1203475420943260","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"9571_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/1574886313666180730114309","volume":"14","author":"K-M Plachouri","year":"2019","unstructured":"Plachouri K-M, Vryzaki E, Georgiou S (2019) Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview. Curr Drug Saf 14(1):14\u201320. https:\/\/doi.org\/10.2174\/1574886313666180730114309","journal-title":"Curr Drug Saf"},{"issue":"3","key":"9571_CR7","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.3390\/ijms24032651","volume":"24","author":"T Zubair","year":"2023","unstructured":"Zubair T, Bandyopadhyay D (2023) Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities. Int J Mol Sci 24(3):2651. https:\/\/doi.org\/10.3390\/ijms24032651","journal-title":"Int J Mol Sci"},{"issue":"4","key":"9571_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","volume":"55","author":"ALC Agero","year":"2006","unstructured":"Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55(4):657\u2013670. https:\/\/doi.org\/10.1016\/j.jaad.2005.10.010","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"9571_CR9","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1200\/jco.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201\u20131208. https:\/\/doi.org\/10.1200\/jco.2004.10.182","journal-title":"J Clin Oncol"},{"issue":"9","key":"9571_CR10","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/jco.2002.10.112","volume":"20","author":"M Ranson","year":"2002","unstructured":"Ranson M et al (2002) ZD1839, a selective oral epidermal growth factor receptor\u2013tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20(9):2240\u20132250. https:\/\/doi.org\/10.1200\/jco.2002.10.112","journal-title":"J Clin Oncol"},{"issue":"6","key":"9571_CR11","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1159\/000513233","volume":"237","author":"A Jacot","year":"2021","unstructured":"Jacot A, Bessis D, Jorda E, Fabbro M, Pujol J-L (2021) Incidence of adverse cutaneous reactions to epidermal growth factor receptor inhibitors in patients with non-small-cell lung cancer. Dermatology 237(6):929\u2013938. https:\/\/doi.org\/10.1159\/000513233","journal-title":"Dermatology"},{"issue":"3","key":"9571_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4103\/0019-5154.131398","volume":"59","author":"U Khopkar","year":"2014","unstructured":"Khopkar U, Madke B, Gole P, Kumar P (2014) Dermatological side effects of epidermal growth factor receptor inhibitors: \u2018Pride\u2019 complex. Indian J Dermatol 59(3):271. https:\/\/doi.org\/10.4103\/0019-5154.131398","journal-title":"Indian J Dermatol"},{"issue":"6","key":"9571_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","volume":"15","author":"TJ Price","year":"2014","unstructured":"Price TJ et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15(6):569\u2013579. https:\/\/doi.org\/10.1016\/S1470-2045(14)70118-4","journal-title":"Lancet Oncol"},{"key":"9571_CR14","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.3816\/clc.2006.s.008","volume":"8","author":"R Perez-Soler","year":"2006","unstructured":"Perez-Soler R (2006) Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 8:S7\u2013S14. https:\/\/doi.org\/10.3816\/clc.2006.s.008","journal-title":"Clin Lung Cancer"},{"issue":"13","key":"9571_CR15","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1158\/1078-0432.ccr-04-0189","volume":"10","author":"J Park","year":"2004","unstructured":"Park J et al (2004) Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 10(13):4383\u20134388. https:\/\/doi.org\/10.1158\/1078-0432.ccr-04-0189","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9571_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","volume":"22","author":"AG Sacco","year":"2021","unstructured":"Sacco AG et al (2021) Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol 22(6):883\u2013892. https:\/\/doi.org\/10.1016\/S1470-2045(21)00136-4","journal-title":"Lancet Oncol"},{"issue":"2","key":"9571_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-4632.2011.05082.x","volume":"51","author":"AM Wnorowski","year":"2012","unstructured":"Wnorowski AM, de Souza A, Chachoua A, Cohen DE (2012) The management of EGFR inhibitor adverse events: a case series and treatment paradigm. Int J Dermatol 51(2):223\u2013232. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05082.x","journal-title":"Int J Dermatol"},{"key":"9571_CR18","doi-asserted-by":"publisher","unstructured":"Tomkov\u00e1 et al (2010) Cetuximab-induced cutaneous toxicity. J Eur Acad Dermatol Venereol 24(6):692\u2013696. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03490.x","DOI":"10.1111\/j.1468-3083.2009.03490.x"},{"issue":"3","key":"9571_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2017","unstructured":"Sibaud V (2017) Dermatologic reactions to immune checkpoint inhibitors. Am J Clin Dermatol 19(3):345\u2013361. https:\/\/doi.org\/10.1007\/s40257-017-0336-3","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"9571_CR20","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1007\/s00520-022-07257-2","volume":"30","author":"MK Ibraheim","year":"2022","unstructured":"Ibraheim MK, Lo J, Gupta R, Parseghian C, Patel AB (2022) Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients. Support Care Cancer 30(10):8051\u20138058. https:\/\/doi.org\/10.1007\/s00520-022-07257-2","journal-title":"Support Care Cancer"},{"issue":"4","key":"9571_CR21","doi-asserted-by":"publisher","first-page":"e1004969","DOI":"10.1080\/23723556.2015.1004969","volume":"2","author":"M Holcmann","year":"2015","unstructured":"Holcmann M, Sibilia M (2015) Mechanisms underlying skin disorders induced by EGFR inhibitors. Molecular & Cellular Oncology 2(4):e1004969. https:\/\/doi.org\/10.1080\/23723556.2015.1004969","journal-title":"Molecular & Cellular Oncology"},{"key":"9571_CR22","doi-asserted-by":"publisher","unstructured":"Bhardwaj M, Chiu MN, Pilkhwal Sah S (2022) Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol 41(1):73\u201390. https:\/\/doi.org\/10.1080\/15569527.2022.2034842","DOI":"10.1080\/15569527.2022.2034842"},{"issue":"1","key":"9571_CR23","doi-asserted-by":"publisher","first-page":"1848058","DOI":"10.1080\/2162402X.2020.1848058","volume":"9","author":"D Tougeron","year":"2020","unstructured":"Tougeron D et al (2020) Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). Oncoimmunology 9(1):1848058. https:\/\/doi.org\/10.1080\/2162402X.2020.1848058","journal-title":"Oncoimmunology"},{"issue":"20","key":"9571_CR24","doi-asserted-by":"publisher","first-page":"e176567","DOI":"10.1172\/JCI176567","volume":"134","author":"CJ Kao","year":"2024","unstructured":"Kao CJ et al (2024) Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures. J Clin Invest 134(20):e176567. https:\/\/doi.org\/10.1172\/JCI176567","journal-title":"J Clin Invest"},{"issue":"13","key":"9571_CR25","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1158\/1078-0432.ccr-23-3431","volume":"30","author":"ME Lacouture","year":"2024","unstructured":"Lacouture ME et al (2024) Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways. Clin Cancer Res 30(13):2822\u20132834. https:\/\/doi.org\/10.1158\/1078-0432.ccr-23-3431","journal-title":"Clin Cancer Res"},{"key":"9571_CR26","doi-asserted-by":"publisher","unstructured":"Mittmann N, Seung SJ (2011) Rash rates with EGFR inhibitors: meta-analysis. Curr Oncol 18(2). https:\/\/doi.org\/10.3747\/co.v18i2.605","DOI":"10.3747\/co.v18i2.605"},{"issue":"12","key":"9571_CR27","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/ijd.15163","volume":"59","author":"JFJ Rovers","year":"2020","unstructured":"Rovers JFJ, Bovenschen HJ (2020) Dermatological side effects rarely interfere with the continuation of checkpoint inhibitor immunotherapy for cancer. Int J Dermatol 59(12):1485\u20131490. https:\/\/doi.org\/10.1111\/ijd.15163","journal-title":"Int J Dermatol"},{"issue":"7","key":"9571_CR28","doi-asserted-by":"publisher","first-page":"6805","DOI":"10.3390\/curroncol30070498","volume":"30","author":"Y Teng","year":"2023","unstructured":"Teng Y, Yu S (2023) Molecular mechanisms of cutaneous immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. Curr Oncol 30(7):6805\u20136819. https:\/\/doi.org\/10.3390\/curroncol30070498","journal-title":"Curr Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09571-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T18:03:32Z","timestamp":1749492212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09571-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["9571"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09571-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In conducting the chart review, we adhered to the ethical standards set forth by relevant institutional policies and IRB guidelines, which ensure the protection of patient confidentiality and data integrity. The review was performed in compliance with the Health Insurance Portability and Accountability Act (HIPAA), relevant IRB-approved protocols, and in accordance with FDA regulations, including 45 CFR 46 (The Common Rule) and ICH E6 (guidelines for good clinical practice). This ensures that all personal health information remained secure and de-identified as required.\u00a0This study was conducted in accordance with the United States\u00a0Code of Federal Regulations Title 45-Part 46 Protection of Human Subjects (45 CFR 46).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for the publication of images in Figs.\u00a0A and B.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"524"}}